Stock Abbreviation: Hepalink
Stock Code: 300199
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
2026 Restricted Stock Incentive Plan
(Draft) Summary
July 2026
Statement
The Company and all directors guarantee that this incentive plan and its summary do not contain any false records, misleading statements, or major omissions, and bear individual and joint legal responsibility for their truthfulness, accuracy, and completeness.
Special Notice
-
This incentive plan is formulated in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures for Equity Incentives of Listed Companies, the Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange, the Guidelines for Self-Regulation of Listed Companies on the ChiNext Market of the Shenzhen Stock Exchange No. 1 - Business Handling, the Articles of Association of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., and other relevant regulations.
-
The incentive instrument for this plan is restricted stock (Type II restricted stock). The source of the shares is A-share common shares repurchased by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") from the secondary market and/or issued via private placement.
-
This incentive plan intends to grant no more than 19.50 million restricted shares to the incentive targets, accounting for approximately 2.21% of the Company's total share capital at the time of the announcement of this draft. Of this, 17.35 million shares will be granted for the first time, accounting for approximately 1.96% of the total share capital and approximately 88.97% of the total equity proposed to be granted; 2.15 million shares are reserved, accounting for approximately 0.24% of the total share capital and approximately 11.03% of the total equity proposed to be granted.
As of the date of the announcement of this draft, the total number of underlying shares involved in all of the Company's effective equity incentive plans does not exceed 20.00% of the Company's total share capital at the time of this announcement. The total number of company shares granted to any single incentive target under all effective equity incentive plans does not exceed 1.00% of the Company's total share capital at the time of this announcement.
From the date of the announcement of this draft until the completion of the vesting of the restricted shares, if the Company undergoes capital reserve conversion, stock dividend distribution, stock split, rights issue, or share consolidation, the number of restricted shares granted shall be adjusted accordingly.
- The number of incentive targets for the initial grant under this plan shall not exceed 111 people, including directors, senior management, company (including subsidiaries) management, and other core business (technical) personnel. It does not include independent directors, shareholders or actual controllers who individually or collectively hold more than 5% of the listed company's shares, or their spouses, parents, or children. This complies with Article 8.4.2 of the Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange, and the targets do not fall under the following circumstances:
(1) Being identified as an inappropriate candidate by a stock exchange in the last 12 months;
(2) Being identified as an inappropriate candidate by the China Securities Regulatory Commission (CSRC) and its dispatched agencies in the last 12 months;
(3) Being subject to administrative penalties or market entry bans by the CSRC and its dispatched agencies in the last 12 months due to major violations of laws and regulations;
(4) Having circumstances stipulated by the Company Law that prohibit serving as a director or senior manager of the company;
(5) Being prohibited by laws and regulations from participating in equity incentives of listed companies;
(6) Other circumstances recognized by the CSRC.